
Berkeley University of California Berkeley

University of California San Francisco



HEAL





Essential Data for Informed Ibogaine Decisions

Data Available Around Ibogaine Research



Health Economics Analysis for Ibogaine

DELPHI

The Price of Despair

The Economic and Human Toll of the Opioid Crisis

Healthcare Costs

Individuals with opioid use disorder incur substantially higher healthcare expenses—exceeding three times the average per capita spending.

Economic Costs

Estimated to exceed \$1.5 trillion in direct healthcare expenses, lost productivity, and criminal justice costs (CDC, JEC).




Lives Lost

Over 80,000 lives are lost to opioid overdose each year in the US, reflecting a tragic public health emergency.

Efficacy Gap

Current treatment paradigms have seen little innovation in decades, providing insufficient relief for patients in need of effective, sustained recovery.

States Recognizing the Need for a Solution



Health Economics Analysis for Ibogaine

🖙 DELPHI

A Beacon of Transformation in Addiction Recovery

Reinventing Lives, Rewriting Futures

Imagine a treatment that doesn't just ease withdrawal—it radically redefines the battle against opioid dependence. Ibogaine therapy delivers that promise:



Experience a dramatic easing of withdrawal, offering a smoother, safer passage through the detox process.

\$14M

In 2024, NIDA awarded a \$14 million grant to develop a cardiac-safe ibogaine analog.

This isn't just temporary relief. A significant number of patients break free from the cycle of opioid use, reclaiming their lives and futures.

The funding supports research into ibogaine's potential for treating substance use disorders.

Malcolm, B. J., Polanco, M., & Barsuglia, J. P. (2018)

Missing Economic Information for Decision Makers

Understanding the Financial Implications of Ibogaine Legislation

Economic

Analysis

Essential



Financial Data Missing

Robust economic studies are needed to show how ibogaine therapy can lower treatment costs, improve patient outcomes, and comply with legal standards. Detailed cost estimates and comprehensive impact studies provide the key evidence that fills the current financial data gap, enabling a clearer picture of ibogaine's benefits.



Better Decisions

With solid financial insights, policymakers can make smarter, data-driven legal and ethical investment choices that drive sustainable change in opioid treatment.



Multi-State Health Economics Proposal

Unveiling Cost Savings for Ibogaine Therapy: A Health Economic Analysis

HEAL: A comprehensive financial analysis revealing potential cost savings for states by implementing ibogaine therapy for opioid addiction under state-level initiatives.

- Reduction in State Healthcare Costs: Demonstrates significant savings by reducing emergency care usage, long-term treatment expenses, and relapse rates.
- Societal Benefits: Proactively addressing the opioid crisis to lower expenditures related to criminal justice and lost productivity.

Support for Emerging State Therapies: Aligns with the objectives of state-led initiatives and emerging therapies organizations, reinforcing evidence-based legislative proposals.

Designed to fit as a fundable line item in emerging therapy budgets.

Comprehensive Analysis: \$559,000 to cover data access, analysis, stakeholder engagement, and project coordination.

Part of a Broader Initiative: This project is a pillar of the larger HOPE initiative, which includes analyses of four additional psychedelic-assisted therapies.

Immediate and Future Impacts: Helps legislators visualize and measure the direct financial benefits while promoting long-term mental health advancements for constituents.





Validating Value of Ibogaine Therapy

Targeted Study for Cost-Effectiveness of Opioid Use Disorder Treatment

Heath Innovation **Cost-Effectiveness** Demonstrating Impact Our work centers on evaluating By demonstrating clear health We are conducting a focused the economic impact of project to analyze the and economic benefits, we aim to ibogaine's potential to alleviate cost-effectiveness of ibogaine equip decision-makers with the opioid withdrawal symptoms and evidence needed to drive therapy for opioid use disorder support long-term recovery. withdrawal symptoms. sustainable innovation in opioid addiction treatment.



Igniting Capital for Care Innovation

Driving Economic Growth for Novel Treatments

Potential Policy & Payer Impact >>>

- Enable CMS and other public payers to understand ROI of covering these innovative therapies.
- Empower lawmakers and policy makers to make informed budget decisions—supporting government investments in research, care delivery infrastructure, and other projects.
- Prime commercial health insurers to adopt coverage for these innovative therapies.

Economic Transformation >>>

- May help unlock a significant influx of capital into the sector, fueling rapid growth and innovation.
- De-risks investment through comprehensive economic analysis that attracts substantial new funding.
- Lays the foundation for transformative financial support, positioning mental healthcare for swift, scalable change.

Our Research Approach

Rigorous Analysis for Policy Impact

HEAL aims to provide concrete evidence of these therapies' cost-effectiveness and demonstrate its potential to significantly reduce healthcare expenditures.

A Data-Driven Approach

In contrast to earlier academic studies, HEAL uses real-world healthcare data from CMS (Medicaid).

Modeling Techniques

HOPE employes sophisticated health economic modeling techniques to project the long-term costs and benefits.













Our Education Approach

Equipping State Leaders with Strategic, Science-Based Insights on Ibogaine Therapy

An essential companion to the HEAL research initiative, *Ibogaine 101* delivers targeted, scientifically grounded content to ensure policymakers are informed and prepared to act.

Curriculum Focus

The program covers ibogaine's neurobiological mechanisms, clinical efficacy for opioid use disorder, safety protocols, and regulatory considerations. Content is drawn from leading federal and academic sources, including work with HHS and UC Berkeley, and guided by experts like Dr. Andrea Barthwell.

Delivery Model

Three professionally narrated video modules (20 minutes each) are designed for rapid absorption and accessible on both desktop and mobile. Supplementary materials—like one-pagers and summary briefs—equip policymakers with concise, actionable insights on demand.

Project Timeline and Deliverables

Policy Briefs, Educational Videos, Academic Publications & Implementation Guides

Foundation & Initial Analysis	Dataset Analysis	Synthesis and Integration
(Months 1-4)	(Months 5-8)	(Months 9-12)
 Platform Development & Data Acquisition Initial Ibogaine Use Disorder (OUD) Modeling Stakeholder Alignment & Analysis Plan Finalization 	 Medicaid Data Integration & Cleaning Ibogaine Intervention Impact Modeling Legislature Education 	 Publications in Top-Tier Academic Journals Final Outputs: Policy Briefs, Reports & Implementation Guides Dissemination and Legislative Engagement

Health Economics Analysis for Ibogaine

DELPHI

Meet the Team

Core Research Team ↓	Academic Partners↓	Data Implementation ↓	Project Management↓
Elliot Marseille, PhD Director, CEP at UCSF/Berkeley Project Research Lead James 'Jim' G. Kahn, PhD Emeritus Professor, UCSF Health Policy & Economics	Julian Urrutia Ripoll, MD, PhD Yale University Health Economics Specialist Anton Avanceña, PhD University of Texas at Austin Health Policy Research Michael Darden, PhD, MPH Johns Hopkins University Substance Use Disorder	Desislava Prodanova, M.A. President, MSIDE Healthcare Systems Engineer Sylvestre Quevedo, MD Vice-President, MSIDE Healthcare Data Analyst	Lia Mix, M.S., LMFT CEO, Delphi Strategic Guidance & Project Management Floris Wolswijk, MSc Senior Project Manager, Delphi Project Coordination Martha Hammel Advisor, Delphi Stakeholder Engagement

Breakdown of Project Expenditures

This 12-month project will cost \$559,000* and produce data and presentations for policymakers in 15 states and 2 academic papers. The research will help government officials, insurance companies, and healthcare systems decide if and how to include these treatments in standard medical care.

Economic Analysis & I	Modeling ↓	Data Costs ↓	Project Management↓	Education ↓
Principal Investigator \$48,500	Research Assistant <i>\$52,000</i>	Data Access (Medicaid) <i>\$25,000</i>	Project Coordination \$76,700	Education Development <i>\$25,000</i>
Senior Analyst <i>\$156,000</i>	Other Academic Costs \$4,500	Data Management \$50,000	PR & Stakeholder Engagement <i>\$43,300</i>	
Data Analyst <i>\$78,000</i>				

*The figures presented exclude an 8% administrative fee charged by Addiction is a Dis-Ease Foundation—the nonprofit entity responsible for managing fund flows for the project.



Who needs this information?

Data-driven Decisions Lead to Better Outcomes





Be a Champion for Addiction Treatment Innovation

Join us in transforming how states address the opioid crisis through groundbreaking research

Your support of the HEAL initiative will drive critical research on ibogaine therapy, delivering evidence-based, cost-effective solutions for opioid use disorder.

- Champion bold, data-driven responses to the addiction crisis
- Help bring breakthrough treatments like ibogaine to the communities that need them most
- Drive systemic change in how we understand, fund, and deliver addiction care

Ready to make an impact? Contact <u>lia.mix@delphi-circle.com</u> to learn how you can champion this vital research





Health Economics Analysis for Ibogaine

DELPHI

44.829 Lives Lost Each Year to Drug Overdoses

